| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 921 | 2008 |
| The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects D Voora, SH Shah, I Spasojevic, S Ali, CR Reed, BA Salisbury, ... Journal of the American college of cardiology 54 (17), 1609-1616, 2009 | 485 | 2009 |
| The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014 | 396 | 2014 |
| The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ... Clinical Pharmacology & Therapeutics 92 (1), 112-117, 2012 | 337 | 2012 |
| Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype D Voora, C Eby, MW Linder, PE Milligan, BL Bukaveckas, HL McLeod, ... Thrombosis and haemostasis 93 (04), 700-705, 2005 | 236 | 2005 |
| Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention LH Cavallari, CR Lee, AL Beitelshees, RM Cooper-DeHoff, JD Duarte, ... JACC: Cardiovascular Interventions 11 (2), 181-191, 2018 | 220 | 2018 |
| Genetic-based dosing in orthopedic patients beginning warfarin therapy EA Millican, PA Lenzini, PE Milligan, L Grosso, C Eby, E Deych, G Grice, ... Blood, The Journal of the American Society of Hematology 110 (5), 1511-1515, 2007 | 215 | 2007 |
| Phenotype standardization for statin‐induced myotoxicity A Alfirevic, D Neely, J Armitage, H Chinoy, RG Cooper, R Laaksonen, ... Clinical Pharmacology & Therapeutics 96 (4), 470-476, 2014 | 210 | 2014 |
| A host-based RT-PCR gene expression signature to identify acute respiratory viral infection AK Zaas, T Burke, M Chen, M McClain, B Nicholson, T Veldman, EL Tsalik, ... Science translational medicine 5 (203), 203ra126-203ra126, 2013 | 133 | 2013 |
| A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans D Voora, DC Koboldt, CR King, PA Lenzini, CS Eby, R Porche‐Sorbet, ... Clinical Pharmacology & Therapeutics 87 (4), 445-451, 2010 | 121 | 2010 |
| The pharmacogenetics of coumarin therapy D Voora, HL McLeod, C Eby, BF Gage Future Medicine Ltd 6 (5), 503-513, 2005 | 117 | 2005 |
| Effect of genetic variations on ticagrelor plasma levels and clinical outcomes C Varenhorst, N Eriksson, A Johansson, BJ Barratt, E Hagström, ... European heart journal 36 (29), 1901-1912, 2015 | 113 | 2015 |
| Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response D Voora, SH Shah, CR Reed, J Zhai, DR Crosslin, C Messer, ... Circulation: Cardiovascular Genetics 1 (2), 100-106, 2008 | 95 | 2008 |
| Clinical application of cardiovascular pharmacogenetics D Voora, GS Ginsburg Journal of the American College of Cardiology 60 (1), 9-20, 2012 | 93 | 2012 |
| Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter‐directed atrial fibrillation ablation TW Wallace, BD Atwater, JP Daubert, D Voora, AL Crowley, TD Bahnson, ... Journal of cardiovascular electrophysiology 21 (8), 849-852, 2010 | 78 | 2010 |
| The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real‐world setting LH Cavallari, AL Beitelshees, KV Blake, LG Dressler, JD Duarte, A Elsey, ... Clinical and translational science 10 (3), 143, 2017 | 75 | 2017 |
| Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events D Voora, D Cyr, J Lucas, JT Chi, J Dungan, TA McCaffrey, R Katz, ... Journal of the American College of Cardiology 62 (14), 1267-1276, 2013 | 73 | 2013 |
| Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics AL Beitelshees, D Voora, JP Lewis Pharmacogenomics and Personalized Medicine, 43-61, 2015 | 72 | 2015 |
| The pharmacogenetics of antiplatelet agents: towards personalized therapy? T Ahmad, D Voora, RC Becker Nature Reviews Cardiology 8 (10), 560-571, 2011 | 62 | 2011 |
| Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ... Clin Pharmacol Ther 92 (1), 112-117, 2012 | 55 | 2012 |
